The University of Minnesota seeks patent protection for a test it claims can determine the effectiveness of leukemia treatments for individual patients far earlier than is now possible.
"Parker’s team is creating an assay system using engineered peptides as probes capable of precisely monitoring the activities of cancer-related signaling enzymes known as tyrosine kinases. Tyrosine kinases with genetic mutations have been identified as one of the key drivers in the spread of cancerous tumors, and the ability more closely track them is the key to the potential medical value of the new biosensor technology."
The full story was published in March, 2017, in Twin Cities Business.